Wenjing Zhum MD, PhD

Articles by Wenjing Zhum MD, PhD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

ByDapeng Wu, MD, PhD,Juanjuan Cui, MD,Wenjing Zhum MD, PhD,Tao Qin, MD,Hanlin Xu, MD

March 20th 2026

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

Latest Updated Articles

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer
March 20th 2026

Wenjing Zhum MD, PhD

Articles by Wenjing Zhum MD, PhD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

From Conference to Practice: Top 5 Takeaways From EHA 2026

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma

Evaluating Bladder-Sparing Strategies and Key GU Data From ASCO 2026

Revolutionizing Oncology in the Digital Age: Effects on Health Care Providers

Givastomig Earns FDA Fast Track Designation in HER2-Negative Gastric Cancer